Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon
Moodys

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIMOLOL

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Timolol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004641 A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis Completed Yale University Phase 2 1993-05-01 OBJECTIVES: I. Evaluate the efficacy of a certain drug in preventing intestinal complications in patients with cirrhosis and high blood pressure in the hepatic portal vein. II. Evaluate vein pressure measurements to predict the development of internal bleeding.
NCT00004641 A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 1993-05-01 OBJECTIVES: I. Evaluate the efficacy of a certain drug in preventing intestinal complications in patients with cirrhosis and high blood pressure in the hepatic portal vein. II. Evaluate vein pressure measurements to predict the development of internal bleeding.
NCT00006398 Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1993-08-01 The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Timolol

Condition Name

Condition Name for Timolol
Intervention Trials
Ocular Hypertension 108
Glaucoma 68
Open-angle Glaucoma 38
Glaucoma, Open-Angle 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Timolol
Intervention Trials
Glaucoma 146
Ocular Hypertension 123
Hypertension 109
Glaucoma, Open-Angle 102
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Timolol

Trials by Country

Trials by Country for Timolol
Location Trials
United States 319
Italy 22
Canada 21
Germany 20
Greece 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Timolol
Location Trials
California 29
Texas 21
Pennsylvania 18
Florida 16
New York 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Timolol

Clinical Trial Phase

Clinical Trial Phase for Timolol
Clinical Trial Phase Trials
Phase 4 75
Phase 3 71
Phase 2/Phase 3 4
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Timolol
Clinical Trial Phase Trials
Completed 146
Recruiting 29
Unknown status 13
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Timolol

Sponsor Name

Sponsor Name for Timolol
Sponsor Trials
Alcon Research 37
Allergan 35
Pfizer 14
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Timolol
Sponsor Trials
Industry 150
Other 94
U.S. Fed 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Moodys
Boehringer Ingelheim
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.